Risultati di ricerca
Background: The optimum post-remission treatment (PRT) in acute myeloid leukaemia (AML) is still a matter of debate. Consolidation treatments include chemotherapy with high-dose cytarabine, or allogeneic or autologous haemopoietic stem cell transplantation (HSCT). In a post-hoc analysis of the AML96 trial ( NCT00180115 ), our aim was to ...
- Markus Pfirrmann, Gerhard Ehninger, Christian Thiede, Martin Bornhäuser, Michael Kramer, Christoph R...
- 2012
23 dic 2011 · In a post-hoc analysis of the AML96 study, we investigated whether we could define prognostic and predictive groups with significantly different probabilities of post-remission survival for patients with AML who were treated with high-dose cytarabine, or autologous or allogeneic HSCT in a priority-based and risk-adapted manner.
- Markus Pfirrmann, Gerhard Ehninger, Christian Thiede, Martin Bornhäuser, Michael Kramer, Christoph R...
- 2012
12 ago 2010 · We present an analysis of prognostic factors derived from a trial in patients with acute myeloid leukemia older than 60 years. The AML96 trial included 909 patients with a median age of 67 years (range, 61-87 years). Treatment included cytarabine-based induction therapy followed by 1 consolidation. ….
- Christoph Röllig, Christian Thiede, Martin Gramatzki, Walter Aulitzky, Heinrich Bodenstein, Martin B...
- 2010
15 gen 2016 · Cytarabine dose of 36 g/m(2) compared with 12 g/m(2) within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study.
- Friedrich Stölzel, Brigitte Mohr, Michael Kramer, Uta Oelschlägel, Tilmann Bochtler, Wolfgang E. Ber...
- 2016
31 mag 2011 · The AML96 trial included 1,862 patients ≥ 18 years old with primary and secondary or treatment-related AML and refractory anemia with excess of blasts according to the French-American-British (FAB) classification.
- Christoph Röllig, Martin Bornhäuser, Christian Thiede, Franziska Taube, Michael Kramer, Brigitte Moh...
- 2011
8 set 2021 · The evaluation of bone marrow morphology by experienced hematopathologists is essential in the diagnosis of acute myeloid leukemia (AML); however, it suffers from a lack of standardization...
20 nov 2009 · A total of 318 patients with sAML (mdsAML = 239 and tAML = 79) were treated within the AML96 trial with a median follow-up for patients alive of 5.66 years (95% CI 4.426 – 6.895). All patients received double induction chemotherapy.
